Skip to main content

Table 1 Characteristics of the participants

From: Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study

Characteristic TBQT-AFEB group (n = 132) TBQT-ALEB group (n = 50) LBQT group (n = 182)
Age (yrs), mean ± SD 47.1 ± 11.2 47.2 ± 12.1 48.09 ± 13.6
Male 52% (68/132) 52% (26/50) 47% (86/182)
Smoker 19% (25/132) 20% (10/50) 12% (21/182)
Drinker 20% (26/132) 20% (10/50) 26% (48/182)
BMI (kg/m2) 23.21 ± 2.96 22.70 ± 3.20 22.69 ± 3.54
Family history 22% (29/132) 22% (11/50) 19% (34/182)
Peptic ulcer disease 20% (27/132) 20% (10/50) 15% (28/182)
Chronic atrophic gastritis with intestinal metaplasia 36% (47/132) 36% (18/50) 39% (71/182)
Gastrointestinal symptoms 38% (50/132) 38% (19/50) 41% (75/182)
Clarithromycin resistance 57% (75/132) 56% (28/50) 59% (107/182)
  1. TBQT tailored, bismuth-based quadruple therapy, amoxicillin + levofloxacin or furazolidone + esomeprazole + colloidal bismuth pectin, LBQT levofloxacin- and bismuth-based quadruple therapy, amoxicillin + levofloxacin + esomeprazole + colloidal bismuth pectin, BMI body mass index
\